行情

SYN

SYN

SYNTHETIC
AMEX

实时行情|Nasdaq Last Sale

0.5000
-0.0194
-3.74%
盘后: 0.5300 +0.03 +6.00% 18:18 02/20 EST
开盘
0.5220
昨收
0.5194
最高
0.5220
最低
0.5000
成交量
11.48万
成交额
--
52周最高
0.8499
52周最低
0.3650
市值
840.32万
市盈率(TTM)
-0.2639
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SYN 新闻

  • Synthetic Biologics FY EPS $(0.98) Up From $(4.06) YoY
  • Benzinga.3小时前
  • 世卫组织:国际专家组正在中国开展实地工作
  • 央视.5小时前
  • 澳门赌场20日零时重开 进门得填健康申报表
  • 环球网.6小时前
  • 应对贫富不均印尼部长出奇招:贫富联姻消除贫困
  • 环球网.6小时前

更多

所属板块

生物技术和医学研究
+0.09%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

SYN 简况

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).
展开

Webull提供Synthetic Biologics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。